Oversight of Laboratory Developed Tests (LDTs) Andrew C. Fish, Executive Director NCCS Cancer Policy Advocate Training November 13, 2014.

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

FDA QS reg/CLIA Comparison: Overview
1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Regulatory Pathway for Platform Technologies
A Review of Codevelopment and Companion Dx Policy Elizabeth Mansfield, PhD Director, Personalized Medicine Staff OIR/CDRH/FDA NCCS Cancer Policy Roundtable.
The Impact of Gynecologic Pathology Diagnostic Errors on Patient Care Dana Marie Grzybicki MD, PhD Colleen M. Vrbin, BA Danielle Pirain, BS Stephen S.
Principles of FDA Regulation for In Vitro Diagnostic Tests for Home Use Carol C. Benson OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel.
SALDA In Vitro Diagnostics in South Africa Welcome 5 November 2014 Portfolio Committee Bill
Cap.org v. # Pathologists’ Role in Coordinated Care and Managing Patient Populations.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
510k Submission Overview Myraqa, Inc. August 22, 2012.
FDA oversight of in vitro diagnostics and other medical devices
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
FDA’s History with Lab Developed Tests Public Meeting on Oversight of Laboratory Developed Tests July 19 – 20, 2010 Courtney C. Harper, Ph.D. Office of.
Why Are We Here? The History and Landscape of DTC Genetic Tests Elizabeth Mansfield, Ph.D. OIVD/CDRH/FDA March 8, 2011 Molecular and Clinical Genetics.
Introduction to Regulation
What Do Toxicologists Do?
Medical Devices Approval Process
QUALITY ASSURANCE IN BLOOD BANKING
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Kenneth Sisco, MD, PhD, FCAP Medical Director Quest Diagnostics
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
CLIA COMPLIANCE. What is CLIA? In 1988 Congress turned its attention to deficiencies in the quality of services provided by the nation’s laboratories.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
FDA Regulation of Diagnostic Tests
FDA Regulation of In Vitro Diagnostic Tests FDA Regulation of In Vitro Diagnostic Tests George Washington University March 8, 2011 Katherine Serrano Office.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Regulatory Considerations for Investigational Assays: Planning for Success Elizabeth Mansfield, PhD OIVD/FDA “Next-Generation DNA Sequencing as a Tool.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Cap.org v. FNL FDA: Challenges to Protecting Public Health – Pathology’s Perspective Roger D. Klein, M.D., JD, F.C.A.P. March 7, 2013 Advocacy.
Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.
INTRODUCTION TO RA.
Local Public Health System Assessment using the NPHPSP Local Instrument Essential Service 6 Enforce Laws and Regulations that Protect Health and Ensure.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
FDA’s Draft LDT Framework & Personalized Medicine Update
Andrew Attia, Miriam Bishay & Carly Sterling September 15, 2015 Diagnostic Blood Testing PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
NICE - in evidence based commissioning Gateshead Council Gillian Mathews, Implementation Consultant - North 9 September 2011.
Who makes up all these rules?? A discussion on Regulatory Agencies and how they relate to each other and our lab.
Guidance Training CFR §483.75(i) F501 Medical Director.
Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee March 10, 2006 Elliot P. Cowan,
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Investigational Devices and Humanitarian Use Devices June 2007.
National Public Health Performance Standards Local Assessment Instrument Essential Service:6 Enforce Laws and Regulations that Protect Health and Ensure.
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Specialties and your career. Starting work in a lab When you apply for your first job in a laboratory it will be in a specific discipline: haematology.
Healthcare Scientists Biomedical Scientists. Science in the service of life A career in Biomedical Science.
CAREERS IN PATHOLOGY. PATHOLOGY Pathology is described as “the study of disease” or in other words the scientific study of the way things go wrong In.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Introduction to Quality Assurance. Quality assurance vs. Quality control.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
FDA and LDT Laurel Estabrooks, PhD, FACMG VP Genetics Business Development SCC Soft Computers.
Regulatory Updates Health Sciences Authority Singapore
CHAPTER 22 LABORATORY CAREERS
FDA’s IDE Decisions and Communications
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Get Ready for FDA Oversight of Laboratory Developed Tests Presenter:
Diagnostic Services in Healthcare
Medical Laboratory Science
Introduction To Medical Technology
Research Operations and Lab Services
Presentation transcript:

Oversight of Laboratory Developed Tests (LDTs) Andrew C. Fish, Executive Director NCCS Cancer Policy Advocate Training November 13, 2014

AdvaMedDx.org2 Presentation Overview  Who is AdvaMedDx?  What are diagnostics and how are they currently regulated?  What are the concerns with LDTs?  How does FDA plan to oversee LDTs?  Questions/Discussion

AdvaMedDx.org4 What are Diagnostics?  Diagnostics are tests performed on samples taken from the body, such as blood, tissue, and urine.  Clinical Chemistry  Examples: Urinalysis; blood glucose monitor. Measuring essential chemicals to monitor basic bodily functions and uncover abnormalities.  Hematology & Cytology  Examples: Pap tests; blood cell counts. Assessment of blood functions; identification of cellular pathologies.  Immunochemistry and Microbiology  Examples: tumor marker tests, HIV antibody tests, streptococcal throat tests, and urinary tract tests. Detection and identification of disease-causing agents, like bacteria and viruses, as well as the proteins, hormones, and anti- bodies related to the functions of the body’s immune system.

AdvaMedDx.org5 What are Diagnostics? cont’d  Molecular Diagnostics  Molecular diagnostic tests detect target proteins and specific genetic sequences (“biomarkers”) to help identify disease presence, type, progression, and recurrence risk.  Examples: multivariate-index test to determine risk of breast cancer recurrence; BRAF mutation test to determine late stage melanoma patient candidates for targeted drug therapy.  These advanced diagnostic tests help clinicians tailor care to subpopulations and individuals—enabling targeted “personalized medicine.” An important component of personalized medicine is the emerging field of companion diagnostics, in which a molecular diagnostic test is used to identify whether a specific drug (companion with the test) is right for an individual patient.

AdvaMedDx.org6 Cancer Diagnostics  Screening  Diagnosis (taxonomy of cancer evolving from site-specific to genetic)  Prognosis/Recurrence Risk  Treatment Selection  Monitoring/Follow up

AdvaMedDx.org7 Evaluating Diagnostics  Food, Drug, & Cosmetic Act: “safe and effective” as determined by FDA  Means:  Analytically valid – meets claim of what it measures and how accurately  Clinically valid – the thing measured is relevant to the disease (and, in many cases, to a care decision)

AdvaMedDx.org8 What is Risk?  Risk = possibility of harm to patient that could result if test results are incorrect  Higher risk:  When a false result could lead to incorrect and harmful clinical management, an unnecessary invasive procedure, or failure to follow up on a serious condition  The purpose of FDA review is to assure availability of safe and effective tests – for the protection of patients.

AdvaMedDx.org9 What are Laboratory Developed Tests?  Diagnostic tests are  (1) produced by manufacturers for distribution to laboratories or other users, or  (2) produced in and offered by laboratories for use in their own facilities – these are laboratory developed tests (LDTs).  In addition to LDTs used in professional settings, some labs are marketing their own tests directly to consumers – including genetic tests claiming to identify disease risk.

AdvaMedDx.org10 So What is the Issue?  Although both statute and regulation cover LDTs, FDA does not currently enforce its regulations for LDTs.  FDA does enforce regulate diagnostics that manufacturers sell to laboratories and other users – requiring pre-market assurance of safety and effectiveness.  Since 1976, FDA has generally exercised enforcement discretion for LDTs.  Why? Because, at that time, LDTs generally were well- understood and relatively simple low risk-tests, or used for rare conditions for which adequate validation would not be feasible.  Now, LDTs encompass even the most advanced molecular diagnostics, such as technically complex genetic tests that guide cancer treatment.

AdvaMedDx.org11 Why the Concern with LDTs? FDA:  “Diagnostic tests are playing an increasingly important role in clinical decision making and disease management, particularly in the context of personalized medicine.”  “LDTs are often used to assess high-risk but relatively common diseases and conditions and to inform critical treatment decisions.”  “Even when FDA-approved tests are available for a disease or condition, laboratories often continue to use LDTs that have not been reviewed by the agency.”  “LDTs that have not been properly validated for their intended use put patients at risk. Risks include risk of missed diagnosis, wrong diagnosis, and failure to receive appropriate treatment.”

AdvaMedDx.org12 So Who Oversees Lab Developed Tests Now?  The Centers for Medicare and Medicaid Services (CMS) has oversight authority of clinical laboratories under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).  CLIA establishes laboratory quality standards and ensures that labs are following good lab practices, including testing procedures and the employment of credentialed lab personnel. But  CLIA is not a substitute for FDA oversight.  Only FDA has the resources and expertise to review LDTs for safety and effectiveness.

AdvaMedDx.org13 What CLIA Does Not Do  CMS itself has said CLIA regulations are not a substitute for FDA oversight. Many critical features of FDA oversight are missing from CLIA. Furthermore, CMS does not have the expertise or resources to oversee LDTs in the same manner as FDA.  Unlike FDA oversight of diagnostics, CLIA:  Does not regulate the safety and effectiveness of diagnostic tests;  Does not require pre-market review of tests;  Does not require demonstration of clinical validity (whether the test is meaningful for clinical decision making);  Does not require systematic adverse event reporting;  Does not have a process for corrections or recalls.  A test is a test—and presents the same risk for patients regardless of whether it is developed by a manufacturer or a laboratory. Potential harms to patients whose tests return incorrect results include unnecessary treatments, with their accompanying costs and side effects, and treatment delay or failure to obtain appropriate treatment, all of which lead to worse outcomes for those patients.

AdvaMedDx.org14 Calls for Reform Are Not New  April 2008: HHS Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS) issues report: US System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services  Calls upon FDA to “address all laboratory tests, regardless of how they are produced (i.e., as a commercial test kit or laboratory- developed test)”.

AdvaMedDx.org15 Stakeholders Endorse FDA Oversight  Numerous Cancer Advocacy Groups, incl.  American Cancer Society  American Association for Cancer Research  Ovarian Cancer National Alliance  Cancer Leadership Council  National Coalition for Cancer Survivorship  American Society of Clinical Oncology  American Heart Association  College of American Pathologists  National Health Council  College of American Pathologists  Society for Women’s Health Research  AIDS Institute  Alliance for Aging Research  Men’s Health Network

AdvaMedDx.org16 FDA Proposed LDTs Framework  October – Draft Guidance: “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).”  Defines LDT as a test “intended for clinical use and designed, manufactured and used within a single laboratory”  A risk-based approach – start with high risk tests and phase in enforcement over time (9 years).  LDTs divided into current three risk categories – Class I (low), Class II (moderate), and Class III (high)

AdvaMedDx.org17 Exceptions For Low Risk and Special Needs Enforcement discretion re. Premarket Review & Quality Systems Requirements* Low risk LDTs (Class I) LDTs for rare diseasesTraditional LDTsLDTs for unmet needs Continued Enforcement Discretion LDTs for solely forensic LDTs used in organ, stem cell, and tissue transplantation *Notification/registration and listing and adverse events reporting required

AdvaMedDx.org18 LDTs for Rare Diseases must meet definition of a Humanitarian Use Device (fewer than 4,000 patients per year tested with the LDT) LDTs for rare diseases

AdvaMedDx.org19 Traditional LDTs Both manufactured and used by a health care facility laboratory (such as a hospital or clinic) for a patient being diagnosed and/or treated at that same health care facility or within the facility’s healthcare system Comprised of only legally marketed components and instruments; AND Interpreted by qualified lab professionals, without the use of automated instrumentation or software interpretation “Traditional LDTs” factors include:

AdvaMedDx.org20 LDTs for Unmet Needs Both manufactured and used by a health care facility laboratory (such as a hospital or clinic) for a patient being diagnosed and/or treated at that same health care facility or within the facility’s healthcare system; AND No FDA cleared or approved IVD available for that specific intended use LDTs for Unmet Needs factors include:

AdvaMedDx.org21 Regulatory Requirements for All LDTs Notification or Registration and listing Adverse event reporting

AdvaMedDx.org22 Regulatory Requirements for High and Moderate Risk LDTs (9 Year Phase In) Notification or Registration and listingPremarket reviewQuality system requirementsAdverse event reporting

AdvaMedDx.org23 Implementation Timeline for All LDTs After Final Guidance At Six months– Notification completed and/or Registration and listing and adverse event reporting At 12 months– Premarket review for initial high risk (class III) devices At 24 months– Priority list for remaining high risk (Class III) devices with submission starting 12 months later At 4 years– FDA releases priority list for moderate risk (Class II ) devices At 5 years– FDA completes phased-in enforcement of premarket review for Class III & commences Class II Phase in At 9 years– moderate risk LDTs phased in

AdvaMedDx.org24 What Happens Now?  Stakeholders will comment on draft guidance (comments close February 2 nd )  FDA will issue final guidance (timing uncertain)  Stay tuned regarding Congressional interest

Questions?